XML 99 R24.htm IDEA: XBRL DOCUMENT
v2.4.1.9

14. SEGMENTS | 6 Months Ended | 12 Months Ended
--- | --- | ---
Sep. 30, 2014 | Mar. 31, 2014
Segment Reporting [Abstract] |  |
SEGMENTS | 14. SEGMENTS We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. ESI did not have any operations in the six months ended September 30, 2013. Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment. The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:
|  | Six Months Ended September 30, |
|  | 2014 |  |  | 2013 |
Revenues: |  |  |  |  |  |  |  |
Aethlon |  | $ | 530,371 |  |  | $ | 840,483 |
ESI |  |  | – |  |  |  | – |
Total Revenues |  | $ | 530,371 |  |  | $ | 840,483 |
Operating Losses: |  |  |  |  |  |  |  |
Aethlon |  | $ | (1,294,453 | ) |  | $ | (1,013,592 | )
ESI |  |  | (445,674 | ) |  |  | – |
Total Operating Loss |  | $ | (1,773,200 | ) |  | $ | (1,013,592 | )
Net Losses: |  |  |  |  |  |  |  |
Aethlon |  | $ | (4,202,873 | ) |  | $ | (3,653,168 | )
ESI |  |  | (356,539 | ) |  |  | – |
Net Loss Before Non-Controlling Interests |  | $ | (4,592,485 | ) |  | $ | (3,653,168 | )
Cash: |  |  |  |  |  |  |  |
Aethlon |  | $ | 47,865 |  |  | $ | 8,754 |
ESI |  |  | 478,322 |  |  |  | – |
Total Cash |  | $ | 526,187 |  |  | $ | 8,754 |
Total Assets: |  |  |  |  |  |  |  |
Aethlon |  | $ | 443,027 |  |  | $ | 411,190 |
ESI |  |  | 646,242 |  |  |  | – |
Total Assets |  | $ | 1,089,269 |  |  | $ | 411,190 |
Capital Expenditures: |  |  |  |  |  |  |  |
Aethlon |  | $ | – |  |  | $ | – |
ESI |  |  | – |  |  |  | – |
Capital Expenditures |  | $ | – |  |  | $ | – |
Depreciation and Amortization: |  |  |  |  |  |  |  |
Aethlon |  | $ | 8,885 |  |  | $ | 4,727 |
ESI |  |  | 9,791 |  |  |  | – |
Total Depreciation and Amortization |  | $ | 18,676 |  |  | $ | 4,727 |
Interest Expense: |  |  |  |  |  |  |  |
Aethlon |  | $ | 156,799 |  |  | $ | 216,502 |
ESI |  |  | – |  |  |  | – |
Total Interest Expense |  | $ | 156,799 |  |  | $ | 216,502 |
| 14. SEGMENTS We operate our businesses principally through two reportable segments: Aethlon, which represents our therapeutic business activities, and ESI, which represents our diagnostic business activities. Our reportable segments have been determined based on the nature of the potential products being developed. ESI did not have any operations in the fiscal year ended March 31, 2013. Aethlon’s revenue is generated primarily from government contracts to date and ESI does not yet have any revenues. We have not included any allocation of corporate overhead to the ESI segment. The following tables set forth certain information regarding our segments and other operations that conforms to the consolidated balance sheet and statement of operations presented in this Report:
|  | Fiscal Years Ended March 31, |
|  | 2014 |  |  | 2013 |
Revenues: |  |  |  |  |  |  |  |
Aethlon |  | $ | 1,623,769 |  |  | $ | 1,230,004 |
ESI |  |  | – |  |  |  | – |
Total Revenues |  | $ | 1,623,769 |  |  | $ | 1,230,004 |
Operating Losses: |  |  |  |  |  |  |  |
Aethlon |  | $ | (2,651,863 | ) |  | $ | (3,575,354 | )
ESI |  |  | (404,065 | ) |  |  | – |
Total Operating Loss |  | $ | (3,055,928 | ) |  | $ | (3,575,354 | )
Net Losses: |  |  |  |  |  |  |  |
Aethlon |  | $ | (13,357,232 | ) |  | $ | (4,892,040 | )
ESI |  |  | (81,730 | ) |  |  | – |
Net Loss Before Non-Controlling Interests |  | $ | (13,438,962 | ) |  | $ | (4,892,040 | )
Cash: |  |  |  |  |  |  |  |
Aethlon |  | $ | 208,259 |  |  | $ | 125,274 |
ESI |  |  | 1,042,020 |  |  |  | – |
Total Cash |  | $ | 1,250,279 |  |  | $ | 125,274 |
Total Assets: |  |  |  |  |  |  |  |
Aethlon |  | $ | 597,026 |  |  | $ | 496,694 |
ESI |  |  | 1,098,076 |  |  |  | – |
Total Assets |  | $ | 1,695,102 |  |  | $ | 496,694 |
Capital Expenditures: |  |  |  |  |  |  |  |
Aethlon |  | $ | 37,313 |  |  | $ | – |
ESI |  |  | 58,743 |  |  |  | – |
Capital Expenditures |  | $ | 96,056 |  |  | $ | – |
Depreciation and Amortization: |  |  |  |  |  |  |  |
Aethlon |  | $ | 11,549 |  |  | $ | 10,484 |
ESI |  |  | 9,538 |  |  |  | – |
Total Depreciation and Amortization |  | $ | 21,087 |  |  | $ | 10,484 |
Interest Expense: |  |  |  |  |  |  |  |
Aethlon |  | $ | 1,282,638 |  |  | $ | 1,132,314 |
ESI |  |  | 4,583 |  |  |  | – |
Total Interest Expense |  | $ | 1,287,221 |  |  | $ | 1,132,314 |

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration